Trials / Completed
CompletedNCT03437083
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 340 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to observe efficacy in terms of progression-free survival rate at 6 months in eribulin-treated breast cancer participants retrospectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eribulin mesylate | intravenous infusion |
Timeline
- Start date
- 2018-01-25
- Primary completion
- 2018-06-30
- Completion
- 2018-06-30
- First posted
- 2018-02-19
- Last updated
- 2019-01-25
Locations
14 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03437083. Inclusion in this directory is not an endorsement.